To overcome the need of prioritizing mutations based on tumor tissue genomics, Martínez-Sáez and colleagues sequenced plasma samples from 45 patients with CDK4/6i-treated HR+/HER2− MBC using the standardized Guardant360 assay [57]. This evidence concerns the gene CDK4 and neoplasm.